Vertex receives chmp positive opinion for kaftrio® (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor for children with cystic fibrosis ages 2 through 5

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the european medicines agency's (ema) committee for medicinal products for human use (chmp) adopted a positive opinion for the label extension of kaftrio® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor, for the treatment of children with cystic fibrosis (cf) ages 2 through 5 years old who have at least one f508del mutation in the cystic fibrosis transmembrane conductance.
VRTX Ratings Summary
VRTX Quant Ranking